Intestinal dendritic cells and epithelial barrier dysfunction in Crohn's disease

Inflammatory Bowel Diseases

Volumn 15, Issue 3, 2009, Pages 436-453

  Silva, Manuel A ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Crohn's disease; Dendritic cells; Epithelial permeability

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; DECTIN 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; COMORBIDITY; CROHN DISEASE; DENDRITIC CELL; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; INNATE IMMUNITY; INTESTINE EPITHELIUM; INTESTINE FISTULA; INTESTINE MUCOSA PERMEABILITY; INTESTINE ULCER; MICROFLORA; PERSONAL HYGIENE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SMOKING; SOCIAL STATUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION; VIRUS INFECTION; ANIMAL; CELL MEMBRANE PERMEABILITY; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL MEMBRANE PERMEABILITY; CROHN DISEASE; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR;

EID: 66149119045     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20660     Document Type: Review

References (190)

1. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathological and clinical entity. JAMA. 1932;99:1323-1329.
2. Lesniowski A. Pamietnik Towarzystwa Lekarskiego Warszawskiego. 1904;100:630-631.
3. Dalziel TK. Chronic interstitial enteritis. Br Med J. 1913;2:1068-1070.
4. Moschcowitz E, Wilensky AD. Non-specific granulomata of the intestine. Am J Med Sci. 1923;166:48-66.
5. Gupta N, Bostrom AG, Kirschner BS, et al. Gender differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics. 2007;120:e1418-e1425.
6. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133:1670-1689.
7. Economou M, Pappas G. New global map of Crohn's disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008;14:709-720.
8. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis. 2007;8:171-178.
9. Gent AE, Hellier MD, Grace RH, et al. Inflammatory bowel disease and domestic hygiene in infancy. Lancet. 1994;343:766-767.
10. Rook GA, Brunet LR. Microbes, immunoregulation, and the gut. Gut. 2005;54:317-320.
11. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
12. Bernstein CN, Rawsthorne P, Cheang M, et al. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol. 2006;101:993-1002.
13. Amre DK, Lambrette P, Law L, et al. Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn's disease: a case-control study. Am J Gastroenterol. 2006;101:1005-1011.
14. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
15. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in Nod2 associated with susceptibility to Crohn's disease. Nature. 2001;411: 603-606.
16. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004;36: 476-480.
17. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn's disease. Nat Genet. 2004;36:471-475.
18. Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology. 2000; 119:23-31.
19. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.
20. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296-1306.
21. Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology. 2006;130:1764-1775.
22. D'Souza, Y, Dionne S, Seidman, EG, et al. No evidence of persisting measles virus in the intestinal tissues of patients with inflammatory bowel disease. Gut. 2007;56:886-888.
23. Selby W, Pavli P, Crotty B, et al. Antibiotics in Crohn's Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology. 2007;132:2313-2319.
24. Tamboli CP, Neut C, Desreumaux, P, et al. Dysbiosis in inflammatory bowel disease. Gut. 2004;53:1-4.
25. Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12:106-111.
26. Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 2006;55:1760-1767.
27. Scanlan PD, Shanahan F, O'Mahony C, et al. Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol. 2006;44:3980-3988.
28. Martínez-Medina M, Aldeguer X, Gonzalez-Huix F, et al. Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm Bowel Dis. 2006;12:1136-1145.
29. Gophna U, Sommerfeld K, Gophna S, et al. Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J Clin Microbiol. 2006;44:4136-4141.
30. Swidsinski A, Loening-Baucke V, Vaneechoutte M, et al. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis. 2008;14:147-161.
31. Elson CO, Cong Y, McCracken VJ, et al. Experimental models of inflammatory bowel disease reveal innate, adaptive and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 2005; 206:260-276.
32. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994;106:1455-1466.
33. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. 1997;150:823-832.
34. Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol. 1997;159:6276-6282.
35. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
36. Silva MA, Menezes J, Deslandres C, et al. Anti-inflammatory role of interleukin-15 in Crohn's disease. Inflamm Bowel Dis. 2005;11:219-230.
37. Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in Crohn's disease. Gut. 2005;54:488-495.
38. Van den Brande JM, Koehler TC, Zelinkova Z, et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut. 2007;56: 509-517.
39. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest. 2004;114:1198-1208.
40. Makita S, Kanai T, Oshima S, et al. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol. 2004; 173:3119-3130.
41. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+CD25+high T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868-1878.
42. Brimnes J, Allez M, Dotan I, et al. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol. 2005;174:5814-5822.
43. Denning TL, Kim G, Kronenberg M. Cutting edge: CD4+CD25+ regulatory T cells impaired for intestinal homing can prevent colitis. J Immunol. 2005;174:7487-7491.
44. Huibregtse IL, van Lent AU, van Deventer SJ. Immunopathogenesis of IBD: insufficient suppressor function in the gut? Gut. 2007;56:584-592.
45. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13:139-145.
46. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65-70.
47. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204:1849-1861.
48. Janeway CR Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
49. Kanneganti TD, Lamkanfi M, Núñez, G. Intracellular NOD-like receptors in host defense and disease. Immunity. 2007;27:549-559.
50. Sabroe I, Jones EC, Usher LR, et al. Toll-like receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses. J Immunol. 2002;168:4701-4710.
51. Nagase H, Okugawa S, Ota Y, et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol. 2003;171:3977-3982.
52. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
53. Rumio C, Besusso D, Palazzo M, et al. Degranulation of Paneth cells via Toll-like receptor 9. Am J Pathol. 2004;165:373-381.
54. Eckmann L. Innate immunity and mucosal bacterial interactions in the intestine. Curr Opin Gastroenterol. 2004;20:82-88.
55. Bischoff SC, Kramer S. Human mast cells, bacteria, and intestinal immunity. Immunol Rev. 2007;217:329-337.
56. Gray D, Gray M, Barr T. Innate responses of B cells. Eur J Immunol. 2007;37:3304-3310.
57. Strober W, Murray PJ, Kitani A, et al. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 2006;6: 9-20.
58. Sartor BR. Bacteria in Crohn's disease: mechanisms of inflammation and therapeutic implications. J Clin Gastroenterol. 2007;41: S37-S43.
59. Peyrin-Biroulet L, Chamaillard M. NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease. J Endotoxin Res. 2007;13:135-139.
60. McDevitt HO, Deak BD, Shreffler DC, et al. Genetic control of the immune response. Mapping of the Ir-1 locus. J Exp Med. 1972;135: 1259-1278.
61. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973;137:1142-1162.
62. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med. 1974;139:380-397.
63. Steinman RM, Lustig DS, Cohn, ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. J Exp Med. 1974;139:1431-1445.
64. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419-426.
65. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med. 1985;161:526-546.
66. Inaba K, Schuler G, Witmer MD, et al. The immunologic properties of purified Langerhans cells: distinct requirements for the stimulation of unprimed and sensitized T lymphocytes. J Exp Med. 1986; 164:605-613.
67. Witmer-Pack MD, Olivier W, Valinsky, J, et al. Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med. 1987; 166:1484-1498.
68. Colonna M, Krug A, Cella, M. Interferon-producing cells: on the front line in immune responses against pathogens. Curr Opin Immunol. 2002;14:373-379.
69. Fiador CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol. 2002;2:77-84.
70. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
71. Steinman RM, Turley S, Mellman I, et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000; 191:411-416.
72. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via αvα5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188:1359-1368.
73. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A. 2002;99:351-358.
74. Quah BJ, O'Neill HC. Maturation of function in dendritic cells for tolerance and immunity. J Cell Mol Med. 2005;9:643-654.
75. Münz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med. 2005;202:203-207.
76. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J Exp Med. 1994;179:1109-1118.
77. Mazzoni A, Segal DM. Controlling the Toll road to dendritic cell polarization. J Leukoc Biol. 2004;75:721-730.
78. Martín-Fontecha A, Sebastián S, Höpken UE, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med. 2003; 198:615-621.
79. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol. 2006;6:476-483.
80. Watanabe N, Wang YH, Lee HK, et al. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature. 2005;436:1181-1185.
81. Luo X, Tarbell KV, Yang H, et al. Dendritic cells with TGF-b1 differentiate naive CD4+CD25+ T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2007;104: 2821-2826.
82. Yamazaki S, Iyoda T, Tarbell K, et al. Direct expansion of functional CD25+ CD4+ regulatory Tcells by antigen processing dendritic cells. J Exp Med. 2003;198:235-247.
83. Tarbell KV, Yamazaki S, Olson K, et al. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004;199:1467-1477.
84. Yamazaki S, Patel M, Harper A, et al. Effective expansion of alloantigen-specific Foxp3+ CD25+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci U S A. 2006;103:2758-2763.
85. Iliev ID, Matteoli G, Rescigno M. The yin and yang of intestinal epithelial cells in controlling dendritic cell function. J Exp Med. 2007; 204:2253-2257.
86. Inaba K, Inaba M, Deguchi M, et al. Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci U S A. 1993;90:3038-3042.
87. Wu L, Li CL, Shortman K. Thymic dendritic cell precursors: relationship to the T lymphocyte lineage and phenotype of the dendritic cell progeny. J Exp Med. 1996;184:903-911.
88. Takeuchi S, Furue M. Dendritic cells: ontogeny. Allergol Int. 2007;56: 215-223.
89. Conti L, Cardone M, Varano B, et al. Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. Eur J Immunol. 2008; 38:750-762.
90. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002;2:151-161.
91. Asselin-Paturel C, Trinchieri G. Production of type I interferons: plasmocytoid dendritic cells and beyond. J Exp Med. 2005;202:461-465.
92. Henri S, Vremec D, Kamath A, et al. The dendritic cell populations of mouse lymph nodes. J Immunol. 2001;167:741-748.
93. Annacker O, Coombes JL, Malmstrom V, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med. 2005;202:1051-1061.
94. Brenan M, Puklavec M. The MRC Ox-62 antigen: a useful marker in the purification of rat veiled cells with the biochemical properties of an integrin. J Exp Med. 1992;175:1457-1465.
95. Voisine C, Hubert FX, Trinité B, et al. Two phenotypically distinct subsets of spleen dendritic cells in rats exhibit different cytokine production and T cell stimulatory activity. J Immunol. 2002;169:2284-2291.
96. Yrlid U, MacPherson GG. Phenotype and function of rat dendritic cell subsets. APMIS. 2003;111:756-765.
97. Hubert FX, Voisine C, Louvet C, et al. Rat plasmacytoid dendritic cells are an abundant subset of MHC class II+ CD4+CD11b-OX62- and type I IFN-producing cells that exhibit selective expression of Toll-like receptors 7 and 9 and strong responsiveness to CpG. J Immunol. 2004;172:7485-7494.
98. Turnbull EL, Yrlid U, Jenkins CD, et al. Intestinal dendritic cell subsets: differential effects of systemic TLR4 stimulation on migratory fate and activation in vivo. J Immunol. 2005;174:1374-1384.
99. Silva MA, Porras M, Jury J, et al. Characterization of ileal dendritic cell distribution in a rat model of acute and chronic inflammation. Inflamm Bowel Dis. 2006;12:457-470.
100. Hubert FX, Voisine C, Louvet C, et al. Differential pattern recognition receptor expression but stereotyped responsiveness in rat spleen dendritic cell subsets. J Immunol. 2006;177:1007-1016.
101. Silva MA, Jury J, Porras M, et al. Intestinal epithelial barrier dysfunction and dendritic cell redistribution during early stages of inflammation in the rat: role for TLR-2 and -4 blockage. Inflamm Bowel Dis. 2008;14:632-644.
102. Wilders MM, Drexhage HA, Kokjé M, et al. Veiled cells in chronic idiopathic inflammatory bowel disease. Clin Exp Immunol. 1984;55: 377-387.
103. Wilders MM, Drexhage HA, Kokjé M, et al. Peripolesis followed by cytotoxicity in chronic idiopathic inflammatory bowel disease. Clin Exp Immunol. 1984;58:614-620.
104. Sarsfield P, Jones DB, Wright DH. Accessory cells in Crohn's disease of the terminal ileum. Histopathology. 1996;28:213-219.
105. Mahida YR, Wu KC, Jewell DP. Characterization of antigen-presenting activity of intestinal mononuclear cells isolated from normal and inflammatory bowel disease colon and ileum. Immunology. 1988;65:543-549.
106. Pavli P, Hume DA, Van de Pol E, et al. Dendritic cells, the major antigen-presenting cells of the human colonia lamina propria. Immunology. 1993;78:132-141.
107. Pavli P, Maxwell L, Van de Pol E, et al. Distribution of human colonic dendritic cells and macrophages. Clin Exp Immunol. 1996;104:124-132.
108. Bell SJ, Rigby R, English N, et al. Migration and maturation of human colonic dendritic cells. J Immunol. 2001;166:4958-4967.
109. te Velde AA, van Kooyk Y, Braat H, et al. Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18-dendritic cell populations in the colonic mucosa of patients with Crohn's disease. Eur J Immunol. 2003;33:143-151.
110. Silva MA, López CB, Riverin F, et al. Characterization and distribution of colonic dendritic cells in Crohn's disease. Inflamm Bowel Dis. 2004;10:504-512.
111. de Baey A, Mende I, Baretton G, et al. A subset of human dendritic cell in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-α. J Immunol. 2003;170:5089-5094.
112. Middel P, Raddatz D, Gunawan B, et al. Increased number of mature dendritic cells in Crohn's disease: evidence for a chemokine mediated retention mechanism. Gut. 2006;55:220-227.
113. de Baey A, Mende I, Riethmueller G, et al. Phenotype and function of human dendritic cells derived from M-DC8(+) monocytes. Eur J Immunol. 2001;31:1646-1655.
114. Silva MA, Quera R, Valenzuela J, et al. Dendritic cells and Toll-like receptors 2 and 4 in the ileum from Crohn's disease patients. Dig Dis Sci. 2008;53:1917-1928.
115. Moody DB. TLR gateways to CD1 function. Nat Immunol. 2006;7: 811-817.
116. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel disease. Gastroenterology. 2005; 129:50-65.
117. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;102:448-455.
118. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;123:689-699.
119. Kramer M, Netea MG, de Jong DJ, et al. Impaired dendritic cell function in Crohn's disease patients with NOD2 3020insC mutation. J Leukoc Biol. 2006;79:860-866.
120. Salucci V, Rimoldi M, Penati C, et al. Monocyte-derived dendritic cells from Crohn patients show differential NOD2/CARD15-dependent immune response to bacteria. Inflamm Bowel Dis. 2008;14: 812-818.
121. Bedford PA, Todorovic V, Westcott ED, et al. Adipose tissue of human omentum is a major source of dendritic cells, which lose MHC clas II and stimulatory function in Crohn's disease. J Leukoc Biol. 2006;80: 546-554.
122. Baumgart DC, Metzke D, Schmitz J, et al. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut. 2005;54:228-236.
123. Gill MA, Blanco P, Arce E, et al. Blood dendritic cells and DC-poietins in systemic lupus erythematosus. Hum Immunol. 2002;63: 1172-1180.
124. Chehimi J, Campbell DE, Azzoni L, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV infected individuals. J Immunol. 2002;168:4796-4801.
125. Bevins CL. Events at the host-microbial interface of the gastrointestinal tract. V. Paneth cell alpha-defensins in intestinal host defense. Am J Physiol Gastrointest Liver Physiol. 2005;289:G173-G176.
126. Corthésy B. Roundtrip ticket for secretory IgA: role in mucosal homeostasis? J Immunol. 2007;178:27-32.
127. Maxson RT, Dunlap JP, Tryka, F, et al. The role of the mucus gel layer in intestinal bacterial translocation. J Surg Res. 1994; 57:682-686.
128. Müller CA, Autenrieth IB, Peschel A. Innate defenses of the intestinal epithelial barrier. Cell Mol Life Sci. 2005;62:1297-1307.
129. Gewirtz AT, Simon PO Jr, Schmitt CK, et al. Salmonella typhimurium translocates flagellin across intestinal epithelia, inducing a proinflammatory response. J Clin Invest. 2001;107:99-109.
130. Nazli A, Yang PC, Jury J, et al. Epithelia under metabolic stress perceive commensal bacteria as a threat. Am J Pathol. 2004;164:947-957.
131. Bambou JC, Giraud A, Menard S, et al. In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain. J Biol Chem. 2004;279:42984-42992.
132. Saegusa S, Totsuka M, Kaminogawa S, et al. Cytokine responses of intestinal epithelial-like Caco-2 cells to non-pathogenic and opportunistic pathogenic yeasts in the presence of butyric acid. Biosci Biotechnol Biochem. 2007;71:2428-2434.
133. Iweala OI, Nagler CR. Immune privilege in the gut: the establishment and maintenance of non-responsiveness to dietary antigens and commensal flora. Immunol Rev. 2006;213:82-100.
134. Macpherson AJ, Geuking MB, McCoy KD. Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria. Immunology. 2005;115:153-162.
135. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004;303:1662-1665.
136. Ballard ST, Hunter JH, Taylor AE. Regulation of tight-junction permeability during nutrient absorption across the intestinal epithelium. Annu Rev Nutr. 1995;15:35-55.
137. Höfer D, Jöns T, Kraemer J. From cytoskeleton to polarity and chemoreception in the gut epithelium. Ann N Y Acad Sci. 1998;859: 75-84.
138. Nusrat A, Turner JR, Madara JL. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol. 2000;279:G851-G857.
139. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 enhances ZO- 1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology. 2004;127:224-238.
140. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology. 2007;132:1359-1374.
141. Howe KL, Reardon C, Wang A, et al. Transforming growth factorbeta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157: H7-induced increased permeability. Am J Pathol. 2005;167:1587-1597.
142. Utech M, Brüwer M, Nusrat A. Tight junctions and cell-cell interactions. Methods Mol Biol. 2006;341:185-195.
143. Cameron HL, Perdue MH. Muscarinic acetylcholine receptor activation increases transcellular transport of macromolecules across mouse and human intestinal epithelium in vitro. Neurogastroenterol Motil. 2007; 19:47-56.
144. Santos J, Yang PC, Söderholm JD, et al. Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. Gut. 2001;48:630-636.
145. Söderholm JD, Streutker C, Yang, PC, et al. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut. 2004;53:1817-1824.
146. Neal MD, Leaphart C, Levy R, et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol. 2006;176:3070-3079.
147. Man AL, Prieto-Garcia ME, Nicoletti C. Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys? Immunology. 2004;113:15-22.
148. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001;2:361-367.
149. Gareau MG, Jury J, MacQueen G, et al. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut. 2007;56:1522-1528.
150. Söderholm JD, Yang PC, Ceponis P, et al. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology. 2002;123:1099-1108.
151. Santos J, Saunders PR, Hanssen NP, et al. Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. Am J Physiol. 1999;277:G391-G399.
152. Santos J, Perdue MH. Stress and neuroimmune regulation of gut mucosal function. Gut. 2000;47(suppl 4):49-51.
153. Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med. 1986;105:883-885.
154. MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920-1925.
155. McGilligan VE, Wallace JM, Heavey PM, et al. Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis. Inflamm Bowel Dis. 2007;13:108-115.
156. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology. 1996;110:1395-1403.
157. Zamora SA, Hilsden RJ, Meddings JB, et al. Intestinal permeability before and after ibuprofen in families of children with Crohn's disease. Can J Gastroenterol. 1999;13:31-36.
158. Fries W, Renda MC, Lo Presti MA, et al. Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn's disease in southern italy. Am J Gastroenterol. 2005;100:2730-2736.
159. Buhner S, Buning C, Genschel J, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut. 2006;55:342-347.
160. D'Incà R, Annese V, di Leo V, et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment Pharmacol Ther. 2006;23:1455-1461.
161. Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology. 2003;124:993-1000.
162. Peeters M, Geypens B, Claus D, et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology. 1997;113:802-807.
163. Söderholm JD, Olaison G, Lindberg E, et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? Gut. 1999;44:96-100.
164. Breslin NP, Nash C, Hilsden RJ, et al. Intestinal permeability is increased in a proportion of spouses of patients with Crohn's disease. Am J Gastroenterol. 2001;96:2934-2938.
165. Hollander D. Inflammatory bowel diseases and brain-gut axis. J Physiol Pharmacol. 2003;54(suppl 4):183-190.
166. Savidge TC, Newman P, Pothoulakis C, et al. Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology. 2007;132:1344-1358.
167. Zeissig S, Bürgel N, Günzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007; 56:61-72.
168. Söderholm JD, Olaison G, Peterson KH, et al. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut. 2002;50:307-313.
169. Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol. 2002;97:2000-2004.
170. Zeissig S, Bojarski C, Buergel N, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut. 2004;53:1295-1302.
171. Söderholm JD, Peterson KH, Olaison G, et al. Epithelial permeability to proteins in the noninflamed ileum of Crohn's disease? Gastroenterology. 1999;117:65-72.
172. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54.
173. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology. 1998;115:1405-1413.
174. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004;127:412-421.
175. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A. 2005; 102:18129-18134.
176. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut. 2004;53:1658-1664.
177. Wehkamp J, Schmid M, Fellermann K, et al. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol. 2005;77:460-465.
178. Nuding S, Fellermann K, Wehkamp J, et al. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut. 2007;56:1240-1247.
179. Marteau P, Colombel JF, Nemeth J, et al. Immunological study of histologically non-involved jejunum during Crohn's disease: evidence for reduced in vivo secretion of secretory IgA. Clin Exp Immunol. 1990;80:196-201.
180. Van de Merwe JP, Schröder AM, Wensinck F, et al. The obligate anaerobic faecal flora of patients with Crohn's disease and their first-degree relatives. Scand J Gastroenterol. 1988;23:1125-1131.
181. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731-734.
182. Sartor BR. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.
183. Wakefield AJ, Fox JD, Sawyerr AM, et al. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn's disease using the nested polymerase chain reaction. J Med Virol. 1992;38:183-190.
184. Yanai H, Shimizu N, Nagasaki S, et al. Epstein-Barr virus infection of the colon with inflammatory bowel disease. Am J Gastroenterol. 1999; 94:1582-1586.
185. Spieker T, Herbst H. Distribution and phenotype of Epstein-Bar virus-infected cells in inflammatory bowel disease. Am J Pathol. 2000;157:51-57.
186. Cottone M, Pietrosi G, Martorana G, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol. 2001;96:773-775.
187. Dimitroulia E, Spanakis N, Konstantinidou AE, et al. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:879-884.
188. Silva MA, López CB, Menezes J, et al. Herpes simplex virus type 1 (HSV-1) infects mature dendritic cells (DCs) in colonic explants from Crohn's disease. Gastroenterology. 2003;124(suppl A):499.
189. Chieppa M, Rescigno M, Huang AY, et al. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. J Exp Med. 2006;203:2841-2852.
190. Porras M, Martín MT, Soler M, et al. Intestinal motor disorders associated with cyclical bacterial overgrowth in a rat model of enteritis. Am J Physiol Gastrointest Liver Physiol. 2004;287:G58-G64.